Introduction
gastrointestinal effects were reported more commonly with fluvoxamine and dermatological effects more often with fluoxetine. Sertraline (1990) and paroxetine (1991 ) Four serotonin selective re-uptake inhibitors (SSRIs) have been marketed in the UK for the treatment of have been more recently marketed. In this paper we present further spontaneous ADR reporting data and depressive illness for several years (fluoxetine, fluvoxamine, paroxetine and sertraline). Only three small scale review and compare the safety profiles of all four SSRIs. Spontaneous adverse drug reaction (ADR) reports are clinical studies allowing comparison of the safety of SSRIs have been published [1] [2] [3] . We have previously made by UK doctors through the 'yellow card' system. The ADROIT (Adverse Drug Reactions On-Line reported that the initial post-marketing safety profiles of fluvoxamine (marketed 1987 ) and fluoxetine (marInformation Tracking) database operated by the Medicines Control Agency (MCA) [ 5] contains over keted 1989 ) based on UK spontaneous adverse drug reaction (ADR) reporting were found to be generally 300,000 spontaneous reports of suspected ADRs to drugs marketed in the UK, constituting an important similar [4 ] : the only apparent differences were that source of safety information. Scrutiny of the reports obtain patients' age and sex, most recent dose of paroxetine before discontinuation, symptoms reported, received leads to the generation of signals of possible safety hazards, which may require further investigation and outcome of the reaction including any treatment.
In 1992 it was noted that we were receiving large using alternative data sources. However the spontaneous reports themselves form a substantial database, with numbers of reports of suspected withdrawal reactions with paroxetine, but not for the other SSRIs, for which details of patients, drugs taken and reactions experienced. In order to be 'user-friendly' the yellow card relatively few such reports were on the database. An article in 'Current Problems in Pharmacovigilance' in report forms request brief details, and so it is sometimes necessary to follow up reports to obtain further details March 1993 [7 ] drew attention to these reports. Because of concern that the reports signalled an important of reactions of interest. In the study described here, reactions reported on discontinuing paroxetine were clinical problem with paroxetine, 217 consecutive reports of withdrawal reaction for that drug received from June systematically followed up with a postal questionnaire to characterise the reactions and obtain details of their 1993 to June 1994 were followed up by sending a standardised questionnaire to the reporting physician. management.
Interpretation of spontaneous ADR reports is subject The questionnaire was posted 3-6 months after receipt of the report at the MCA and asked the following to several biases. If these are recognised and minimised, it can be possible to compare the safety profiles of questions: different products [6 ] . Reporters were also invited to make other relevant comments. the possibility of unrecognised reporting bias cannot be discounted.
The article in 'Current Problems in Pharmacovigilance' in March 1993 [ 7] highlighted the occurThe ADROIT database provides an opportunity to compare the safety profiles of the four SSRIs as they rence of symptoms on drug withdrawal with paroxetine. The reporting rates of this reaction for the four SSRIs are used in clinical practice rather than under the restrictions of clinical trials. Systematic follow-up of prior to March 1993 were therefore compared to avoid the expected effect of publicity bias on reporting. reports of withdrawal reactions reported with paroxetine permits an investigation of a potentially important adverse effect of SSRI medication.
Results

W ithdrawal reactions Methods
The UK spontaneous ADR database was searched for By March 1993 we had received 111 reports of withdrawal reaction with paroxetine, five with sertraline, reports of suspected ADRs with fluvoxamine, fluoxetine, paroxetine and sertraline. The breakdown of total ADRs nine with fluvoxamine and two with fluoxetine. The reporting rate prior to the publication of an article reported by 'system organ class' (SOC, the body system affected by each ADR) was examined, and the numbers referring to withdrawal reactions in our bulletin in March 1993 [7] was 10 times higher with paroxetine of reports of selected ADRs were scrutinised. The number of prescriptions written for each SSRI in (0.3 per thousand) than sertraline and fluvoxamine (0.03), and 100 times higher than with fluoxetine (0.002). England, Wales and Northern Ireland was obtained from the Prescription Pricing Authority (PPA), to
Withdrawal reactions also constituted a much higher proportion of total ADR reports for paroxetine (5.1%) obtain an estimate of the number of reports per 1000 prescriptions, referred to in this paper as the 'reporting than sertraline (0.9%), fluvoxamine (0.4%) or fluoxetine (0.06%). This recording period includes 2 years of rate'. The age and gender of patients prescribed SSRIs in the 12 months to the end of March 1993, and the marketing for paroxetine and sertraline, but longer for fluoxetine and fluvoxamine because of their earlier doses of paroxetine prescribed, were obtained from the Medical Data Index (MDI-International Medical availability. The reporting of withdrawal reactions for fluoxetine and fluvoxamine restricted to the first 2 years Statistics).
Reports of withdrawal reactions with all four SSRIs after marketing began (a period equivalent to the availability of paroxetine and sertraline by March 1993 ) received to the end of July 1994 were scrutinised to revealed rates of 0 and 0.03 per thousand respectively, elderly, but otherwise neither patient age nor gender appeared to influence reporting of withdrawal reactions. and the proportions of total ADRs that were withdrawal reactions were 0 and 0.1% (two reports) respectively. Table 2 summarises the symptoms reported. These were varied: dizziness, paraesthesia, tremor, anxiety, Characteristics of 430 reports (notified by 387 doctors) of withdrawal reactions with paroxetine, 20 with sertranausea and palpitation were the commonest in each of the six symptom groups. There was no clear difference line, 18 with fluoxetine and 9 with fluvoxamine held on the database at the end of July 1994 are shown in between the SSRIs in the nature of symptoms reported. As a consequence of the small numbers of reports for Table 1 . There was similar age and gender distribution among the reports, and a similar proportion of patients sertraline, fluoxetine and fluvoxamine, a dose relationship or time interval between stopping the drug and treated for their symptoms by restarting their medication. Only 1 of 32 reported withdrawal reactions onset of symptoms could not be described. 73% of final doses of paroxetine taken by patients reported with where the outcome was known with sertraline, fluvoxamine and fluoxetine was recorded by the reporting withdrawal reactions were 20 mg day−1. Other doses taken were equally divided between doses higher and doctor as 'not recovered'. In the 12 months to the end of March 1993, 24-30% of prescriptions for any SSRI lower than 20 mg day−1. MDI data show that around 79% of UK paroxetine prescriptions are for 20 mg were to patients aged 40-54 years, with 20-22% aged 30-39 years and 31-36% aged over 55 years and the day−1, 10% for 30 mg day−1 and 7% for 40 mg day−1. The time interval between stopping paroxetine and the female5male ratio of prescriptions were 1.6 for fluvoxamine, 1.9 for paroxetine, 2.1 for fluoxetine and 2.4 for onset of symptoms was available in 160 reports: the median interval was 2.1 days. Symptoms were noted sertraline. Overall, withdrawal reactions tended to be reported more commonly in younger patients than the within 1 day in 21%, within 2 days in 36%, within 3 *as a percentage of those where the outcome was known. **data for paroxetine were gathered differently (i.e. by questionnaire) from the other three SSRIs and so are not directly comparable. The mean number of reports made per doctor was 1.1 ( paroxetine, fluoxetine) and 1.0 (sertraline, fluvoxamine). 
In 146 of the 430 patients (34%) reported to have during the first 2 years of marketing of each SSRI in the UK is shown in Table 4 . Overall, the safety profiles had a withdrawal reaction with paroxetine, the reporter indicated that the patient was treated for their symptoms. and the reporting frequencies of the four SSRIs are similar. In only seven (1.6%) did the reporter confirm that no treatment was given and in 277 the reporter did not Neurological ADRs comprise a greater proportion of reports for paroxetine than for the other three SSRIs, indicate whether treatment was provided. In most cases the treatment was to restart paroxetine. However 16 though the difference is small and the nature of the reactions reported is similar. Reports of extrapyramidal (3.7%) received other medicinal products to manage their symptoms. The duration of the symptoms, stated movements and tremor appear to account for some of this difference. Reports of reactions affecting the reproin 71 of the 284 patients who were not reported to have been treated, lasted from 1 to 52 days (mean 10.5, s.d. ductive system after starting an SSRI comprise a mixture of different symptoms and signs, except for a relatively 10 days). The median duration was 8 days, with 33 (46.5%) recovering in 7 days and a further 29 (41%) high number of reports of impotence and ejaculatory failure with paroxetine. recovering within 8-14 days.
Cardiovascular ADRs are uncommon among the reports. Apart from palpitation, most of the reports were of hypotension including postural hypotension, Survey of doctors reporting withdrawal reactions with which, together with tachycardia, represent 34% of the paroxetine cardiovascular reports for sertraline, 32.9% of those for paroxetine, 29.6% of those for fluvoxamine and 29.3% Questionnaires were sent to 217 doctors of which 194 for fluoxetine. (89.4%) were completed and returned. Doctors gave the following responses to the questions asked:
1 112 (57.7%) had restarted paroxetine because of the withdrawal reaction. Discussion 2 Of these 112, 85 (75.9%) had stopped by the time the questionnaire was completed (3 months or more We have used spontaneous ADR reports and prescribing after the initial report).
information to compare the ADRs reported with 3 Of these 85 patients, 8 stopped paroxetine ≤14 days paroxetine, fluvoxamine, fluoxetine and sertraline. after restarting, a further 17 discontinued between Spontaneous ADR reporting is subject to biases and days 15-28 of treatment and 23 between days 29-42.
confounding variables which influence interpretation. Twenty-five (29%) patients who restarted used paroxHowever the similarity between indications, patient etine for >56 days. Of the 27 who had not stopped demography, exposure and market life for each SSRI paroxetine by the time of the questionnaire, 3 were minimise some of these biases. Other biases such as the continuing it because of a recurrence of depression adverse publicity that stimulated reports of suicides with and in 3 the question was not answered. Thus 21 fluoxetine [4 ] need to be taken into account in any (18.8%) were known to have restarted paroxetine interpretation. Overall the safety profiles of the four because of the withdrawal symptoms and to have SSRIs are broadly similar, in accordance with a recent been continuing with it 3 months or more later as a review [9 ] . consequence.
Only three direct comparisons of different SSRIs in 4 The question on whether additional treatment was the same clinical study have been published [1] [2] [3] . given was completed by 181 respondents (93.2%). 42 These have not been large, and did not detect differences (23.2%) received alternative pharmacological therapy, in the occurrence of serious ADRs. One comparison and 139 had not. The classes and attributed efficacy found more agitation, anxiety and insomnia with of drugs given are shown in Table 3 . 60% of the fluoxetine, but more somnolence, irritability and headdrugs other than paroxetine used were judged by the ache with sertraline [1 ] . We have previously reported reporter to have been effective. differences between fluoxetine and fluvoxamine based 5 21% of reactions were said to be mild, 58% were on spontaneous reports of ADRs [4 ] : fluoxetine has moderately severe, and 21% severe. This question been associated more often with dermatological reacwas not answered by two doctors.
tions, and fluvoxamine more often with upper gastrointestinal symptoms. General disorders (dizziness, malaise, fatigue, insomnia, sedation etc.) were commonly reported with all four SSRIs. Psychiatric ADRs constitute a Profiles of other suspected ADRs greater proportion of the total for fluoxetine than the other SSRIs: publicity given to allegations of a causal Total ADRs reported per thousand prescriptions fell from peaks reached in the first 6 months of marketing association with aggression and suicidal behaviour is likely to have contributed to this difference. The of 30 for fluoxetine, 21 for paroxetine, 18 for fluvoxamine and 14 for sertraline to 2-5 for each product at 24 preponderance of reports of gastrointestinal reactions with fluvoxamine, including nausea and vomiting, was months, demonstrating the well-recognised decline in reporting with time since marketing began [8 ], but with again noted. Cardiovascular toxicity is rarely reported ADRs with paroxetine than the other three SSRIs, though the difference is small. The PEM study did not it appears that male patients on paroxetine may be more likely to experience ejaculatory dysfunction or find a marked difference between fluoxetine, paroxetine and fluvoxamine in the rate of extrapyramidal disorders impotence than users of the other SSRIs. PEM suggested a rate of around 0.7% in the first month for paroxetine, [11] . A rare risk of movement disorders may be a class effect. 14 to 24 times greater than with fluoxetine or fluvoxamine. However the methodology used to detect these Spontaneous ADR reporting in the UK suggests that symptoms occurring after drug discontinuation ADRs appears to be important: other studies have (withdrawal reactions) occur more commonly after are similar to reports with the other SSRIs. Only the reports with paroxetine were followed up intensivparoxetine than after the other SSRIs. We did not identify a cause of reporting bias that could explain ely, and in view of the much smaller number of reports for the other SSRIs qualitative comparisons may be these results. Although the original UK data sheet for paroxetine advised gradual discontinuation (unlike the unreliable. Overall, ADRs reported in the post-marketing setting, other SSRIs), it has not been established that prior knowledge of an ADR increases or decreases the chance and their frequency, are similar for the four SSRIs. Some ADRs are more commonly associated with one of it being reported. Our finding contrasts with the PEM study which did not show a difference in the of the SSRIs than the others, for example gastrointestinal ADRs with fluvoxamine, dermatological and psychiatric frequency of symptoms in the week after discontinuation of three SSRIs [11 ] . Symptoms have been noted to ADRs with fluoxetine, and sexual dysfunction and neurological disorders with paroxetine. Withdrawal occur on withdrawal of other centrally-acting drugs, including tricyclic antidepressants [ 14] . Withdrawal reactions have been reported with all four SSRIs, most frequently with paroxetine, though this study suggests reactions with fluvoxamine, fluoxetine, paroxetine and sertraline have been described in the literature [15] [16] [17] [18] that they are relatively mild and do not have features of a physical drug dependency syndrome. and have been reported spontaneously to us for all four SSRIs. The occurrence of a 'serotonergic-withdrawal' syndrome has been proposed [16 ] , but there is no
We are grateful to the numerous doctors who reported the previous evidence to suggest that it may be more suspected ADRs and completed the questionnaire, and to the common with one of the SSRIs than the others; however Prescription Pricing Authority and International Medical it may be significant that paroxetine is the most Statistics for prescription information and patient demography.
pharmacologically selective antagonist at the serotonin re-uptake site.
The different half-lives of the SSRIs could account for the 100-fold different withdrawal reaction reporting
